FHD-609

FHD-609 is a PROTAC degrader and inhibitor of BRD9 (Bromodomain-containing protein 9) . FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 (HY-49393), Black: linker (HY-168309) ; Pink: (S) -Deoxy-thalidomide-Br (HY-168308) ) [1][2][3][4][5].

Product Specifications

CAS Number

[2676211-64-4]

UNSPSC

12352005

Target

Epigenetic Reader Domain; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fhd-609.html

Purity

99.15

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C(CN2CCC(CN3CCC4(CN(C5=CC(C(N([C@@H]6C(NC(CC6)=O)=O)C7)=O)=C7C=C5)C4)CC3)CC2)C(OC)=CC(C(C8=C9C=NC(N%10CCC%10)=C8)=CN(C)C9=O)=C1

Molecular Formula

C47H56N8O6

Molecular Weight

829.00

References & Citations

[1]Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT) : disease mechanisms and potential drug targets. Expert Opin Ther Targets. 2022 Mar;26 (3) :187-192. |[2]Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel) . 2022 May 31;14 (11) :2721. |[3]Lin M, et al. Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models[J]. Cancer Research, 2024, 84 (6_Supplement) : 7185-7185.|[4]Collins M, et al. Preclinical validation of target engagement assays and investigation of mechanistic impacts of FHD-609, a clinical-stage BRD9 degrader being developed for the treatment of synovial sarcoma[J]. strategies, 2022, 36: 936-950.|[5]Liu X, et al. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. Molecules. 2023 Jan 26;28 (3) :1217.